The company has posted net profit of Rs.19.8 crores for the period ended December 31, 2020 as against net loss of Rs. 569.7 crores for the period ended December 31, 2019.
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
In FY 2020-2021 (upto 12th January 2021) Jan Aushadhi Kendras have completed sales of Rs. 484 crores at 7,064 Pradhan Mantri Bhartiya Jan Aushadhi Kendras
.jpeg)
One of our major priorities in next 3-5 years is the introduction of a kit-based version of CanAssist Breast, enabling hospitals conduct the test locally
Hospital data reveals a sharp rise in consultations related to hormonal health, erectile dysfunction and male fertility, highlighting growing awareness among younger men.
Approval paves the way for expansion in North America’s growing vascular access market, with innovative SlipStream technology designed to simplify catheter insertion and enhance patient care
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
